Aclaris Therapeutics (ACRS) Equity Average (2017 - 2025)
Historic Equity Average for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $125.9 million.
- Aclaris Therapeutics' Equity Average fell 459.67% to $125.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.9 million, marking a year-over-year decrease of 459.67%. This contributed to the annual value of $156.4 million for FY2024, which is 1185.65% down from last year.
- Per Aclaris Therapeutics' latest filing, its Equity Average stood at $125.9 million for Q3 2025, which was down 459.67% from $137.9 million recorded in Q2 2025.
- Aclaris Therapeutics' 5-year Equity Average high stood at $227.8 million for Q3 2022, and its period low was $75.0 million during Q1 2021.
- Its 5-year average for Equity Average is $167.4 million, with a median of $168.0 million in 2023.
- As far as peak fluctuations go, Aclaris Therapeutics' Equity Average soared by 42791.46% in 2021, and later tumbled by 2623.13% in 2023.
- Aclaris Therapeutics' Equity Average (Quarter) stood at $207.0 million in 2021, then increased by 0.85% to $208.7 million in 2022, then decreased by 24.9% to $156.8 million in 2023, then fell by 8.87% to $142.9 million in 2024, then decreased by 11.85% to $125.9 million in 2025.
- Its last three reported values are $125.9 million in Q3 2025, $137.9 million for Q2 2025, and $149.8 million during Q1 2025.